2.18
+0(+0.00%)
Currency In USD
| Previous Close | 2.18 |
| Open | 2.18 |
| Day High | 2.25 |
| Day Low | 2.08 |
| 52-Week High | 7.46 |
| 52-Week Low | 1.26 |
| Volume | 94,551 |
| Average Volume | 177,093 |
| Market Cap | 59.97M |
| PE | -2.6 |
| EPS | -0.84 |
| Moving Average 50 Days | 1.85 |
| Moving Average 200 Days | 2.1 |
| Change | 0 |
If you invested $1000 in Immix Biopharma, Inc. (IMMX) since IPO date, it would be worth $594.01 as of December 26, 2024 at a share price of $2.18. Whereas If you bought $1000 worth of Immix Biopharma, Inc. (IMMX) shares 2 years ago, it would be worth $1,090 as of December 26, 2024 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
GlobeNewswire Inc.
Dec 19, 2024 2:35 PM GMT
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis Immix Biopharma, Inc. (Nasdaq:IMMX) All four patie
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
GlobeNewswire Inc.
Dec 16, 2024 2:48 PM GMT
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete responses in frail and resistant relapsed/refra
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
GlobeNewswire Inc.
Dec 10, 2024 2:39 PM GMT
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 Immix Biopharma, Inc. (Nasdaq:IMMX) 75% (12/16) complete resp